Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prevention of Meningococcal Infection”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Testing effectiveness (Phase 2)Study completedNCT00560313
What this trial is testing

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Who this might be right for
Meningococcal Disease
Novartis Vaccines 54
Post-approval studies (Phase 4)Not Yet RecruitingNCT07252804
What this trial is testing

Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases

Who this might be right for
Autoimmune Rheumatologic Disease
University of Sao Paulo General Hospital 263
Large-scale testing (Phase 3)Study completedNCT00317109
What this trial is testing

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 168
Testing effectiveness (Phase 2)Study completedNCT00381615
What this trial is testing

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Who this might be right for
Healthy
Novartis Vaccines 147
Large-scale testing (Phase 3)Study completedNCT01423084
What this trial is testing

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 344
Post-approval studies (Phase 4)Study completedNCT00310713
What this trial is testing

Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 33
Post-approval studies (Phase 4)Study completedNCT00271479
What this trial is testing

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Who this might be right for
Infections, MeningococcalMeningitis, Meningococcic
Epicentre 720
Testing effectiveness (Phase 2)Study completedNCT00137917
What this trial is testing

Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 478
Large-scale testing (Phase 3)Study completedNCT00626327
What this trial is testing

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

Who this might be right for
Meningococcal Infections
Novartis Vaccines 1,630
Large-scale testing (Phase 3)Study completedNCT00136604
What this trial is testing

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Who this might be right for
Whole Cell PertussisHaemophilus Influenzae Type bHepatitis B+3 more
GlaxoSmithKline 617
Large-scale testing (Phase 3)Study completedNCT01911221
What this trial is testing

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Who this might be right for
Prevention of the Meningococcal Disease
Novartis Vaccines 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT06647407
What this trial is testing

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Who this might be right for
Meningococcal ImmunizationHealthy Volunteers
Sanofi Pasteur, a Sanofi Company 750
Large-scale testing (Phase 3)Study completedNCT00657709
What this trial is testing

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Who this might be right for
Serogroup B Meningococcal Meningitis
Novartis Vaccines 3,630
Testing effectiveness (Phase 2)Study completedNCT00433914
What this trial is testing

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Who this might be right for
Meningococcal Disease
Novartis Vaccines 60
Post-approval studies (Phase 4)Study completedNCT02724046
What this trial is testing

Ciprofloxacin for the Prevention of Meningococcal Meningitis

Who this might be right for
Meningitis, Meningococcal
Epicentre 300
Post-approval studies (Phase 4)Study completedNCT00316654
What this trial is testing

Persistence of Antibody Response to N. Meningitidis Group C in Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 489
Post-approval studies (Phase 4)Study completedNCT00936962
What this trial is testing

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

Who this might be right for
Meningococcal Sero-type C Infection
University of British Columbia 452
Large-scale testing (Phase 3)Study completedNCT00197275
What this trial is testing

Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants

Who this might be right for
TetanusHepatitis BHaemophilus Influenzae Type b+2 more
GlaxoSmithKline 800
Post-approval studies (Phase 4)Study completedNCT00310687
What this trial is testing

Persistence of Immune Response After Vaccination With MCC

Who this might be right for
Prevention of Meningococcal Infection
Novartis 1,244
Large-scale testing (Phase 3)Study completedNCT00311415
What this trial is testing

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Who this might be right for
Prevention of Meningococcal Infection
Novartis Vaccines 257
Load More Results